Tag Archives: lymphoma

FDA Approves Zynlonta (loncastuximab tesirine-lpyl) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FDA Approves Zynlonta (loncastuximab tesirine-lpyl) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma LAUSANNE, Switzerland–(BUSINESS WIRE) APRIL 23, 2021 — ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after… Read More »

Brukinsa Approved for Relapsed, Refractory Mantle Cell Lymphoma

MONDAY, Nov. 18, 2019 — Brukinsa (zanubrutinib), a kinase inhibitor, has been granted accelerated approval for the treatment of adults with mantle cell lymphoma who have received at least one previous therapy, the U.S. Food and Drug Administration announced last week. The recommended dose of Brukinsa capsules is 160 mg orally twice daily or 320… Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More »